Targets and developments in molecular targeted therapies for liver cancer with cirrhosis
10.3760/cma.j.issn.1007-8118.2011.12.004
- VernacularTitle:硬化型肝癌靶向治疗的目标与应用进展
- Author:
Xianliang LI
;
Dazhi CHEN
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Cirrhosis;
Molecular targeted therapy
- From:
Chinese Journal of Hepatobiliary Surgery
2011;17(12):963-968
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with various genomic alterations.In most patients,HCC is associated with cirrhosis which contributes to treatment morbidity and mortality.Cirrhosis adds difficulties to clinical management of HCC.Over the past decade,several molecular targets which are involved in the etiology of HCC have been identified.Among them,treatment with sorafenib,an antiangiogenic and Raf kinase inhibitor,has shown survival benefit.This represents a breakthrough in treatment of this complex disease,and proves that molecular therapies can be effective in HCC.It is becoming apparent that to overcome the complexity of genomic aberrations in HCC,combination therapies are essential.Several ongoing clinical trials show encouraging results.Future researches are necessary to identify new compounds to block important undruggable pathways,and to identify new oncogenes as targets for therapies through novel high throughout technologies.Ultimately,a molecular classification of HCC based on genome investigations and identification of patient subclasses using drug responsiveness will lead to a more personalized treatment.Although molecular therapy is a promising treatment for HCC with cirrhosis,surgery,if applicable,remains the first choice of treatment.
